Clinical Trial Update: Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial of adoptive transfer of MART1/Melan-A–specific cytotoxic T lymphocytes for malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MART1/Melan-A CTL adoptive transfer

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Melanoma (Skin) | Phase 1 | Status: COMPLETED